FELIMAZOLE 1.25 MG COATED TABLETS FOR CATS

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Nopērc to tagad

Lejuplādēt Produkta apraksts (SPC)
10-05-2017

Aktīvā sastāvdaļa:

THIAMAZOLE

Pieejams no:

Dechra Limited

ATĶ kods:

QH03BB02

SNN (starptautisko nepatentēto nosaukumu):

THIAMAZOLE

Deva:

1.25 mg/tablet

Zāļu forma:

Coated Tablets

Receptes veids:

POM

Ārstniecības grupa:

Feline

Ārstniecības joma:

Thiamazole

Ārstēšanas norādes:

Miscellaneous

Autorizācija statuss:

Authorised

Autorizācija datums:

2013-09-13

Produkta apraksts

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Felimazole 1.25 mg Coated tablets for cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Coated tablet.
Red sugar-coated biconvex tablets 5.5 mm diameter.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the stabilisation of hyperthyroidism in cats prior to surgical
thyroidectomy.
For the long-term treatment of feline hyperthyroidism.
4.3 CONTRAINDICATIONS
Do not use in cats suffering from systemic disease such as primary
liver disease or diabetes mellitus.
Do not use in cats showing signs of autoimmune disease.
Do not use in animals with disorders of white blood cells, such as
neutropenia and lymphopenia.
Do not use in animals with platelet disorders and coagulopathies
(particularly thrombocytopenia).
Do not use in cats with hypersensitivity to thiamazole or the
excipient, polyethylene glycol.
Do not use in pregnant or lactating females.
Please refer to section 4.7.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As thiamazole can cause haemoconcentration, cats should always have
access to drinking water.
1 tablet contains:
ACTIVE SUBSTANCE:
Thiamazole
1.25 mg
EXCIPIENTS:
Titanium Dioxide (E171)
0.51 mg
Dispersed Ponceau 4R Lake (E124)
1.35 mg
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_0_
_6_
_2_
_p_
_a_
_g_
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu